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isinterpretation of
rostate Cancer Data
n a recent issue of the Journal, Lauer (1) suggested that the lack
f effect of prostate-specific antigen (PSA) screening for prostate
ancer is an important reason to be cautious about screening for
ubclinical coronary artery disease. Unfortunately, his argument
ight be fallacious. First, he states that prostate cancer death rates
ave not declined, despite widespread screening. Quite the con-
rary is true. Death rates due to prostate cancer have substantially
eclined in the U.S. from 39.2 to 23.6/100,000 from 1992 to 2006
2–4). This is an age-adjusted decline of approximately 4%/year.
rom 1991 to 2004, prostate cancer mortality has declined much
ore rapidly in the U.S. with the frequent use of PSA testing than
n the United Kingdom, where there is less screening (4.2%/year in
he U.S. vs. 1.1%/year in the United Kingdom) (5).
Second, he points to the recent report of the PLCO (Prostate,
ung, Colorectal and Ovarian Cancer Screening Trial) that failed
o document benefit of prostate cancer screening with PSA (6).
nfortunately, the PLCO trial was contaminated by high screen-
ng rates in the comparison group and a lack of control for
herapies for prostate cancer. It is estimated that probably 50% of
en 50 years of age and older in the U.S. have a PSA test. Most
ecently, PSA testing was evaluated in a population that was
reviously unexposed to PSA testing. A randomized trial of 20,000
en in Göteborg, Sweden, 50 to 64 years of age at entry were
ollowed an average of 14 years (7). The reduction of prostate
ancer deaths was 40% (range 0.17 to 64) in the PSA screening
ersus control group, p  0.002. Approximately 293 men needed
o be screened and 12 needed to be diagnosed to prevent 1 prostate
ancer death—44 deaths in the intervention versus 78 in the
ontrol group. The effect of PSA testing on reducing mortality in
his study was of similar magnitude as mammography screening for
reast cancer.
A trial to evaluate screening of asymptomatic individuals for the
revention of subsequent clinical coronary artery disease events
i.e., screening asymptomatic individuals with coronary calcium
etection) is impractical. The technology is widely available; its
rognostic implications are well-published; and preventive thera-
ies such as lipid lowering, antihypertensive therapy, and lifestyle
odifications are now accessible and affordable. Such a trial, like
he PLCO trial, will be contaminated by crossovers, use or lack of
se of statins and other effective therapies, and poor compliance
ith dietary and pharmacological therapies. The trial of hard end
oints (i.e., coronary heart disease [CHD] deaths or myocardial
nfarction), will require long follow-up because of the early stage of
ncubation of atherosclerosis in which these individuals will be
etected. Do we really need to prove that lipid lowering is effective
n individuals with atherosclerosis for reducing CHD mortality?
o we need to waste another 7 to 10 years and millions of dollars
f valuable research funds? The key is maximizing the use of
roven effective preventive pharmacological and nonpharmacologi- nal therapies by targeting the population most likely to benefit
rom them and thereby substantially reducing CHD incidence,
ortality, and costs of health care.
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eply
n their thoughtful letter, Drs. Kuller and Edmundowicz challenge
y call for randomized trials of coronary artery screening (1). They
ite U.S./United Kingdom ecological data demonstrating public
ealth benefits from prostate-specific antigen (PSA) screening (2)
nd then cite a just-published randomized trial that found reduced
ortality (3). They argue that, in our current environment, it is
mpractical to execute trials, and even so, they are unnecessary: we
lready know lipid-lowering therapy works.
Numerous authorities have cited the limitations of observational
nalyses of screening; these include lead- and length-time bias,
isattribution bias, and overdiagnosis. Even Collin et al. (2), who
rote the positive ecological study that Kuller and Edmundowicz
ite, conclude their report stating, “We can only continue to
peculate about the relative contributions of differences in detec-
ion and treatment or the relative balance of benefits and harms,
ntil the publication of findings from trials provides the robust
vidence that is so eagerly awaited.” I agree!
Prostate cancer kills far less often than coronary artery disease,
et academic leaders have completed large-scale trials. Two trials
hat enrolled approximately 250,000 patients showed little or no
enefit and much overdiagnosis, whereas 1 trial an order of
agnitude smaller suggests benefit in some patients (3). Academic
eaders have performed screening trials for other less common
iseases, including breast cancer, lung cancer, and aortic aneurysm.
urely we can execute a screening trial for coronary disease, the
ation’s leading cause of death.
